Hepatobiliary Malignancy

2

Review clinical trials related to Hepatobiliary Malignancy. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

Advanced liver and gallbladder malignancies (including liver cancer, cholangiocarcinoma and gallbladder cancer) are a type of disease that is difficult to treat, and most patients have a short survival period. In recent years, immunotherapy (such as PD-1/PD-L1 inhibitors) has brought new hope to these patients, but still only a small number of patients can benefit. Research has found that approximately 40% of patients with liver and gallbladder tumors have symptoms of depression and anxiety, which not only affect their quality of life but may also reduce the therapeutic effect by influencing immune function. Fluoxetine is a commonly used antidepressant. The latest research shows that in addition to improving mood, it may also enhance the anti-tumor effect of immunotherapy. This study aims to explore whether fluoxetine combined with immunotherapy can better control tumors than immunotherapy alone, prolong the survival period of patients, and at the same time improve the depressive and anxious symptoms and quality of life of patients.

Participants needed: 240
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: First Affiliated Hospital of Wenzhou Medical UniversityUpdated: Mar 24, 2026Locations: 1
Eligibility criteria

Age: 18 to 80 years old, both male and female are acceptable. [+10]

Those with uncorrectable coagulation dysfunction and a distinct bleeding tendenc... [+9]

Status: Recruiting

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.

Participants needed: 40
Trial details
Age: 18-75Biological sex: AllType: ObservationalSponsor: Ruijin HospitalUpdated: Dec 11, 2024Locations: 1Duration: 1 Year
Eligibility criteria

Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiri... [+4]

Patients with serious illnesses that researchers consider unsuitable for partici... [+4]